In MJD, aripiprazole treatment in mice reduced ATXN3 aggregation in the cerebellum and brainstem; in particular, it reduced soluble and high molecular weight mutant ATXN3 species but showed limited impact on highly insoluble species [10]. This evidence concerns the gene ATXN3 and Spinocerebellar ataxia type 3.